244 related articles for article (PubMed ID: 28684538)
1. Tissue-type plasminogen activator regulates macrophage activation and innate immunity.
Mantuano E; Azmoon P; Brifault C; Banki MA; Gilder AS; Campana WM; Gonias SL
Blood; 2017 Sep; 130(11):1364-1374. PubMed ID: 28684538
[TBL] [Abstract][Full Text] [Related]
2. Tissue-type plasminogen activator selectively inhibits multiple toll-like receptors in CSF-1-differentiated macrophages.
Das L; Azmoon P; Banki MA; Mantuano E; Gonias SL
PLoS One; 2019; 14(11):e0224738. PubMed ID: 31697716
[TBL] [Abstract][Full Text] [Related]
3. PAI1 blocks NMDA receptor-mediated effects of tissue-type plasminogen activator on cell signaling and physiology.
Gonias SL; Banki MA; Gilder AS; Azmoon P; Campana WM; Mantuano E
J Cell Sci; 2018 Jul; 131(14):. PubMed ID: 29930084
[TBL] [Abstract][Full Text] [Related]
4. Tissue-type plasminogen activator neutralizes LPS but not protease-activated receptor-mediated inflammatory responses to plasmin.
Zalfa C; Azmoon P; Mantuano E; Gonias SL
J Leukoc Biol; 2019 Apr; 105(4):729-740. PubMed ID: 30690783
[TBL] [Abstract][Full Text] [Related]
5. LRP1 assembles unique co-receptor systems to initiate cell signaling in response to tissue-type plasminogen activator and myelin-associated glycoprotein.
Mantuano E; Lam MS; Gonias SL
J Biol Chem; 2013 Nov; 288(47):34009-34018. PubMed ID: 24129569
[TBL] [Abstract][Full Text] [Related]
6. The LRP1/CD91 ligands, tissue-type plasminogen activator, α
Mantuano E; Azmoon P; Banki MA; Gunner CB; Gonias SL
Sci Rep; 2022 Oct; 12(1):17594. PubMed ID: 36266319
[TBL] [Abstract][Full Text] [Related]
7. Enzymatically Inactive Tissue-Type Plasminogen Activator Reverses Disease Progression in the Dextran Sulfate Sodium Mouse Model of Inflammatory Bowel Disease.
Das L; Banki MA; Azmoon P; Pizzo D; Gonias SL
Am J Pathol; 2021 Apr; 191(4):590-601. PubMed ID: 33465348
[TBL] [Abstract][Full Text] [Related]
8. The functional role of the second NPXY motif of the LRP1 beta-chain in tissue-type plasminogen activator-mediated activation of N-methyl-D-aspartate receptors.
Martin AM; Kuhlmann C; Trossbach S; Jaeger S; Waldron E; Roebroek A; Luhmann HJ; Laatsch A; Weggen S; Lessmann V; Pietrzik CU
J Biol Chem; 2008 May; 283(18):12004-13. PubMed ID: 18321860
[TBL] [Abstract][Full Text] [Related]
9. An antibody that targets cell-surface glucose-regulated protein-78 inhibits expression of inflammatory cytokines and plasminogen activator inhibitors by macrophages.
Gunner CB; Azmoon P; Mantuano E; Das L; Zampieri C; Pizzo SV; Gonias SL
J Cell Biochem; 2023 May; 124(5):743-752. PubMed ID: 36947703
[TBL] [Abstract][Full Text] [Related]
10. A Soluble PrP
Mantuano E; Azmoon P; Banki MA; Sigurdson CJ; Campana WM; Gonias SL
J Immunol; 2022 Jan; 208(1):85-96. PubMed ID: 34810220
[TBL] [Abstract][Full Text] [Related]
11. The NMDA receptor functions independently and as an LRP1 co-receptor to promote Schwann cell survival and migration.
Mantuano E; Lam MS; Shibayama M; Campana WM; Gonias SL
J Cell Sci; 2015 Sep; 128(18):3478-88. PubMed ID: 26272917
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activator receptor assemblies in cell signaling, innate immunity, and inflammation.
Gonias SL
Am J Physiol Cell Physiol; 2021 Oct; 321(4):C721-C734. PubMed ID: 34406905
[TBL] [Abstract][Full Text] [Related]
13. Tissue-Type Plasminogen Activator-A296-299 Prevents Impairment of Cerebral Autoregulation After Stroke Through Lipoprotein-Related Receptor-Dependent Increase in cAMP and p38.
Armstead WM; Riley J; Yarovoi S; Higazi AA; Cines DB
Stroke; 2016 Aug; 47(8):2096-102. PubMed ID: 27354223
[TBL] [Abstract][Full Text] [Related]
14. A soluble derivative of PrP
Mantuano E; Azmoon P; Banki MA; Lam MS; Sigurdson CJ; Gonias SL
J Biol Chem; 2020 Oct; 295(41):14178-14188. PubMed ID: 32788217
[TBL] [Abstract][Full Text] [Related]
15. Microglial-mediated PDGF-CC activation increases cerebrovascular permeability during ischemic stroke.
Su EJ; Cao C; Fredriksson L; Nilsson I; Stefanitsch C; Stevenson TK; Zhao J; Ragsdale M; Sun YY; Yepes M; Kuan CY; Eriksson U; Strickland DK; Lawrence DA; Zhang L
Acta Neuropathol; 2017 Oct; 134(4):585-604. PubMed ID: 28725968
[TBL] [Abstract][Full Text] [Related]
16. Isoflurane Postconditioning Inhibits tPA-Induced Matrix Metalloproteinases Activation After Hypoxic Injury via Low-Density Lipoprotein Receptor-Related Protein and Extracellular Signal-Regulated Kinase Pathway.
Kim SY; Cheon SY; Kim EJ; Lee JH; Kam EH; Kim JM; Park M; Koo BN
Neurochem Res; 2017 May; 42(5):1533-1542. PubMed ID: 28303501
[TBL] [Abstract][Full Text] [Related]
17. Evidence that LDL receptor-related protein 1 acts as an early injury detection receptor and activates c-Jun in Schwann cells.
Flütsch A; Henry K; Mantuano E; Lam MS; Shibayama M; Takahashi K; Gonias SL; Campana WM
Neuroreport; 2016 Dec; 27(18):1305-1311. PubMed ID: 27824728
[TBL] [Abstract][Full Text] [Related]
18. Tissue-type plasminogen activator suppresses activated stellate cells through low-density lipoprotein receptor-related protein 1.
Kang LI; Isse K; Koral K; Bowen WC; Muratoglu S; Strickland DK; Michalopoulos GK; Mars WM
Lab Invest; 2015 Oct; 95(10):1117-29. PubMed ID: 26237273
[TBL] [Abstract][Full Text] [Related]
19. The sphingomyelin/ceramide pathway is involved in ERK1/2 phosphorylation, cell proliferation, and uPAR overexpression induced by tissue-type plasminogen activator.
Maupas-Schwalm F; Augé N; Robinet C; Cambus JP; Parsons SJ; Salvayre R; Nègre-Salvayre A
FASEB J; 2004 Sep; 18(12):1398-400. PubMed ID: 15231724
[TBL] [Abstract][Full Text] [Related]
20. Tissue plasminogen activator induces microglial inflammation via a noncatalytic molecular mechanism involving activation of mitogen-activated protein kinases and Akt signaling pathways and AnnexinA2 and Galectin-1 receptors.
Pineda D; Ampurdanés C; Medina MG; Serratosa J; Tusell JM; Saura J; Planas AM; Navarro P
Glia; 2012 Apr; 60(4):526-40. PubMed ID: 22162045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
